| Symbol | AB |
|---|---|
| Name | ALLIANCEBERNSTEIN HOLDING L.P. |
| Sector | FINANCE |
| Region | North America |
| Industry | Investment Managers |
| Address | 501 COMMERCE STREET, NASHVILLE, Tennessee, 37203, United States |
| Telephone | +1 615 622-0000 |
| Fax | — |
| — | |
| Website | https://www.alliancebernstein.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0000825313 |
| Description | AllianceBernstein provides investment management services to institutional (45% of assets under management), retail (39%), and private (16%) clients through products that includes mutual funds, hedge funds, and separately managed accounts. At the end of June 2022, AB had $647.0 billion in managed assets, composed primarily of fixed-income (41% of AUM) and equity (43%) strategies, with other investments (made up of asset allocation services and certain other alternative investments) accounting for the remainder. The company also provides sell-side research and brokerage services through its Sanford Bernstein subsidiary. Additional info from NASDAQ: |
AB Science provides an update on its clinical program, suspending some non-priority clinical trials to focus on two clinical programs
Read moreAB Science fait le point sur son programme clinique avec l’arrêt de certaines études cliniques non prioritaires en vue de se concentrer sur deux programmes cliniques
Read moreAB Science announces the successful completion of a EUR 2.3 million private placement
Read moreAB Science annonce le succès d’un placement privé de 2,3 millions d’euros
Read moreAB Science reports completion of the step 3 of phase 1, evaluating the combination of AB8939 with venetoclax for the treatment of refractory or relapsed AML
Read moreAB Science annonce l’achèvement de l’étape 3 de la phase 1, évaluant la combinaison d’AB8939 et du vénétoclax dans le traitement de la LMA réfractaire ou en rechute
Read moreAB Science patent for masitinib in the treatment of metastatic castrate resistant prostate cancer formally granted in the United States with a protection until 2042
Read moreLe brevet d’AB Science concernant le masitinib dans le traitement du cancer de la prostate métastatique hormono-résistant a été officiellement délivré aux Etats-Unis avec une durée de protection jusqu’en 2042
Read more